Clinical Trials Logo

Recurrent Melanoma clinical trials

View clinical trials related to Recurrent Melanoma.

Filter by:

NCT ID: NCT01217411 Terminated - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer

Start date: October 2010
Phase: Phase 1
Study type: Interventional

This randomized phase I/II trial studies the side effects and the best dose of RO4929097 (gamma-secretase/Notch signalling pathway inhibitor RO4929097) when given together with whole-brain radiation therapy or stereotactic radiosurgery and to see how well it works compared to whole-brain radiation therapy or stereotactic radiosurgery alone in treating patients with breast cancer or other cancers (such as lung cancer or melanoma) that have spread to the brain. RO4929097 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Whole-brain radiation therapy uses high energy x-rays deliver radiation to the entire brain to treat tumors that can and cannot be seen. Stereotactic radiosurgery may be able to deliver x-rays directly to the tumor and cause less damage to normal tissue. It is not yet known whether giving RO4929097 together with whole-brain radiation therapy or stereotactic radiosurgery may kill more tumor cells.

NCT ID: NCT01166126 Terminated - Stage IV Melanoma Clinical Trials

Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV

Start date: October 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out how often two investigational drugs that are given together will shrink the patient's tumor and how well they will prolong the time it takes their tumor to grow. The investigators also wish to find out how they affect certain substances in the patient's tumor and in their blood important for tumor growth. The combination of these drugs is experimental, and has not been proven to help treat melanoma

NCT ID: NCT00945269 Terminated - Stage IV Melanoma Clinical Trials

Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma

Start date: July 2009
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: White blood cells that have been treated in a laboratory may be able to kill tumor cells in patients with melanoma. Aldesleukin and denileukin diftitox may stimulate the white blood cells to kill melanoma cells. Giving therapeutic autologous lymphocyte therapy together with aldesleukin and denileukin diftitox may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects of giving therapeutic autologous lymphocytes together with aldesleukin and denileukin diftitox and to see how well it works in treating patients with stage III-IV melanoma

NCT ID: NCT00303836 Terminated - Stage IV Melanoma Clinical Trials

Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma

Start date: November 2005
Phase: Phase 2
Study type: Interventional

This randomized phase II trial is studying how well giving vaccine therapy with or without interleukin-2 after chemotherapy and an autologous white blood cell infusion works in treating patients with metastatic melanoma. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy with interleukin-2, chemotherapy, and an autologous white blood cell infusion may be a more effective treatment for metastatic melanoma.

NCT ID: NCT00087386 Terminated - Stage IV Melanoma Clinical Trials

Tanespimycin in Treating Patients With Stage III-IV Melanoma

Start date: June 2004
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well tanespimycin works in treating patients with stage III or stage IV melanoma. Antitumor antibiotics such as tanespimycin may stop the growth of melanoma by stopping blood flow to the tumor.

NCT ID: NCT00087373 Terminated - Stage IV Melanoma Clinical Trials

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Start date: June 2004
Phase: Phase 2
Study type: Interventional

Vaccines may make the body build an immune response to kill tumor cells. Injecting a vaccine directly into a tumor may cause a stronger immune response and kill more tumor cells. This phase II trial is studying how well vaccine therapy works in treating patients with metastatic melanoma.

NCT ID: NCT00072189 Terminated - Stage IV Melanoma Clinical Trials

A Phase II Study of UCN-01 in Metastatic Melanoma

Start date: November 2003
Phase: Phase 2
Study type: Interventional

UCN-01 may stop the growth of tumor cells by blocking the enzymes necessary for their growth. This phase II trial is studying how well UCN-01 works in treating patients with metastatic melanoma.

NCT ID: NCT00039091 Terminated - Clinical trials for Recurrent Adult Acute Myeloid Leukemia

Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer

Start date: March 2002
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects of monoclonal antibody therapy in treating patients with ovarian epithelial cancer, melanoma, acute myeloid leukemia, myelodysplastic syndrome, or non-small cell lung cancer. Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells

NCT ID: NCT00006003 Terminated - Stage IV Melanoma Clinical Trials

SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated

Start date: July 2000
Phase: Phase 2
Study type: Interventional

SU5416 may stop the growth of malignant melanoma by stopping blood flow to the tumor. Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic melanoma that has been previously treated

NCT ID: NCT00003552 Terminated - Stage IV Melanoma Clinical Trials

Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma

Start date: January 1999
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of chemotherapy plus peripheral stem cell transplantation in treating patients with metastatic melanoma.